[0005] In one aspect, disclosed herein is method of treating adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome in a human comprising orally administering once daily about 80 mg to about 160 mg of a compound having the structure of Compound 1, or a pharmaceutically acceptable salt thereof:



(Compound 1).

[0005a] In another aspect, the present disclosure provides a use of a compound having the structure of Compound 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome in a human, wherein about 80 mg to about 160 mg of the compound is to be administered orally once daily.

[0006] In some embodiments, the human with ACTH-dependent Cushing's syndrome comprises a pituitary adenoma.

[0007] In some embodiments, the human with ACTH-dependent Cushing's syndrome comprises an ectopic ACTH-secreting tumor. In some embodiments, the ectopic ACTH-secreting tumor is in the lungs, pancreas, thyroid, thymus gland, intestines, adrenal gland, paraganglia, or combinations thereof.

[0008] In some embodiments, treating ACTH-dependent Cushing's syndrome comprises lowering serum cortisol levels, lowering urine cortisol levels, or both. In some embodiments, treating ACTH-dependent Cushing's syndrome comprises lowering cortisol levels in the human by at least 10% from baseline.

[0009] In some embodiments, treating ACTH-dependent Cushing's syndrome comprises lowering levels of serum cortisol, androstenedione, or combinations thereof. In some embodiments, treating ACTH-dependent Cushing's syndrome comprises lowering levels of serum cortisol, androstenedione, or combinations thereof, by at least 10 from baseline.

[0010] In some embodiments, treating ACTH-dependent Cushing's syndrome comprises reducing levels of cortisol, androstenedione (A4), 17-hydroxyprogesterone (17-OHP), aldosterone, dehydroepiandrosterone sulfate (DHEAS), dehydroepiandrosterone (DHEA), or combinations thereof. In some embodiments, treating ACTH-dependent Cushing's

syndrome comprises reducing levels of cortisol, androstenedione (A4), 17-hydroxyprogesterone (17-OHP), aldosterone, dehydroepiandrosterone sulfate (DHEAS), dehydroepiandrosterone (DHEA), or combinations thereof, by at least 10% from baseline.

[0011] In some embodiments, treating ACTH-dependent Cushing's syndrome comprises delaying or eliminating the need for removal of one or both adrenal glands.

CLAIMS

WHAT IS CLAIMED IS:

1. Use of a compound having the structure of Compound 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome in a human, wherein about 80 mg to about 160 mg of the compound is to be administered orally once daily:



(Compound 1).

2. The use of claim 1, wherein the human with ACTH-dependent Cushing's syndrome comprises a pituitary adenoma.

3. The use of claim 1, wherein the human with ACTH-dependent Cushing's syndrome comprises an ectopic ACTH-secreting tumor.

4. The use of claim 3, wherein the ectopic ACTH-secreting tumor is in the lungs, pancreas, thyroid, thymus gland, intestines, adrenal gland, paraganglia, or combinations thereof.

5. The use of any one of claims 1-4, wherein the use comprises lowering serum cortisol levels, lowering urine cortisol levels, or both.

6. The use of claim 5, wherein the use comprises lowering cortisol levels in the human by at least 10% from baseline.

7. The use of any one of claims 1-6, wherein the use comprises lowering levels of serum cortisol, androstenedione, or combinations thereof.

8. The use of claim 7, wherein the use comprises lowering levels of serum cortisol, androstenedione, or combinations thereof, by at least 10% from baseline.

9. The use of any one of claims 1-6, wherein the use comprises reducing levels of cortisol, androstenedione (A4), 17-hydroxyprogesterone (17-OHP), aldosterone, dehydroepiandrosterone sulfate (DHEAS), dehydroepiandrosterone (DHEA), or combinations thereof.

10. The use of claim 9, wherein the use comprises reducing levels of cortisol, androstenedione (A4), 17-hydroxyprogesterone (17-OHP), aldosterone,

dehydroepiandrosterone sulfate (DHEAS), dehydroepiandrosterone (DHEA), or combinations thereof, by at least 10% from baseline.

11. The use of any one of claims 1-10, wherein the use comprises delaying or eliminating the need for removal of one or both adrenal glands.

12. The use of any one of claims 1-11, wherein about 80 mg of Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered.

13. The use of any one of claims 1-11, wherein about 120 mg of Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered.

14. The use of any one of claims 1-11, wherein about 160 mg of Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered.

15. The use of any one of claims 1-14, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered once daily in the evening.